Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1‐specific CD8+ T cells

Abstract Objectives Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8+ T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141+ dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclusi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Frances E Pearson, Kirsteen M Tullett, Ingrid M Leal‐Rojas, Oscar L Haigh, Kelly‐Anne Masterman, Carina Walpole, John S Bridgeman, James E McLaren, Kristin Ladell, Kelly Miners, Sian Llewellyn‐Lacey, David A Price, Antje Tunger, Marc Schmitz, John J Miles, Mireille H Lahoud, Kristen J Radford
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2020-01-01
Col·lecció:	Clinical & Translational Immunology
Matèries:	cancer immunotherapy CD141 CLEC9A dendritic cells vaccines Wilms' tumor 1
Accés en línia:	https://doi.org/10.1002/cti2.1141
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!